Safety and immunogenicity of SIIPL Tdap, a new tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, in healthy subjects 4–65 years of age: A …

I Aydin, M May, F Pisano, N Mpofu-Maetzig, L Grode… - Vaccine, 2023 - Elsevier
Background This study assessed the safety and immunogenicity of a new booster vaccine
against tetanus, diphtheria, and pertussis manufactured by Serum Institute of India Pvt. Ltd …
相关文章 所有 4 个版本
[PDF] tandfonline.com

Safety and immunogenicity of an indigenously developed tetanus toxoid, diphtheria toxoid, and acellular pertussis vaccine (Tdap) in adults, adolescents, and children …

HJ Sharma, S Parekh, P Pujari, S Shewale… - Expert Review of …, 2023 - Taylor & Francis
Background This study assessed safety and immunogenicity of Serum Institute of India Pvt
Ltd (SIIPL)'s tetanus toxoid (TT), diphtheria toxoid (DT), and acellular pertussis booster …
被引用次数：1 相关文章 所有 3 个版本

A randomised, double-blind, non-inferiority clinical trial on the safety and immunogenicity of a tetanus, diphtheria and monocomponent acellular pertussis (TdaP) …

B Thierry-Carstensen, K Jordan, HH Uhlving, T Dalby… - Vaccine, 2012 - Elsevier
BACKGROUND: Increasing incidence of pertussis in adolescents and adults has stimulated
the development of safe and immunogenic acellular pertussis vaccines for booster …
被引用次数：41 相关文章 所有 10 个版本
[HTML] oup.com

Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults

J Mertsola, O Van Der Meeren, Q He… - Clinical infectious …, 2010 - academic.oup.com
Background. Booster vaccination against tetanus and diphtheria at 10-year intervals is
commonly recommended. Reduced antigen content diphtheria and tetanus toxoids and …
被引用次数：106 相关文章 所有 12 个版本

Immunogenicity and safety of a tetanus toxoid, reduced diphtheria toxoid and three-component acellular pertussis vaccine in adults 19–64 years of age

M Blatter, LR Friedland, WM Weston, P Li, B Howe - Vaccine, 2009 - Elsevier
PURPOSE: This study was conducted to assess the immunogenicity and safety of a tetanus
toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine containing three …
被引用次数：62 相关文章 所有 8 个版本

A randomised controlled trial with a diphtheria–tetanus–acellular pertussis (dTpa) vaccine in adults

M Van der Wielen, P Van Damme, E Joossens… - Vaccine, 2000 - Elsevier
The aim of this assessor-blinded trial was to compare the immunogenicity and reactogenicity
of a candidate diphtheria, tetanus toxoids and acellular pertussis vaccine with reduced …
被引用次数：97 相关文章 所有 9 个版本

FDA approval of expanded age indication for a tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine

Centers for Disease Control and … - MMWR. Morbidity …, 2011 - pubmed.ncbi.nlm.nih.gov
On July 8, 2011, the Food and Drug Administration (FDA) approved an expanded age
indication for the tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine …
被引用次数：40 相关文章 所有 2 个版本

Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Boostrix®): results of two randomized …

WM Weston, LR Friedland, X Wu, B Howe - Vaccine, 2012 - Elsevier
BACKGROUND: Pertussis can cause significant morbidity in elderly patients, who can also
transmit this disease to infants and young children. There is little data available on the use of …
被引用次数：84 相关文章 所有 9 个版本

FDA approval of expanded age indication for a tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine

Centers for Disease Control and … - MMWR. Morbidity …, 2009 - pubmed.ncbi.nlm.nih.gov
On December 4, 2008, the Food and Drug Administration (FDA) approved an expanded age
indication for the tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine …
被引用次数：12 相关文章 所有 2 个版本
[HTML] cdc.gov

[HTML][HTML] Use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines: updated recommendations of the Advisory Committee on Immunization …

FP Havers - MMWR. Morbidity and mortality weekly report, 2020 - cdc.gov
Background Two Tdap vaccines are licensed for use in the United States. Boostrix
(GlaxoSmithKline) is approved for a single dose in persons aged≥ 10 years; Adacel (Sanofi …
被引用次数：154 相关文章 所有 8 个版本